EGFR targeted therapy in lung cancer; an evolving story.
EGFR targeted therapy in lung cancer; an evolving story.
复制标题
DOI：
10.1016/j.rmcr.2017.01.016
复制
发表时间：
2017
影响因子：
1.1
通讯作者：
Yiannakis D
中科院分区：
文献类型：
--
作者：
Bartholomew C;Eastlake L;Dunn P;Yiannakis D
具有驱动突变的特定癌基因，如表皮生长因子受体(EGFR 1)基因，可导致非小细胞肺癌的形成。识别这些癌基因、它们的驱动突变和下游效应使药物可以靶向这些途径。这种个性化治疗已成为抗击肺癌的重要战略，并突显了检测这些突变的必要性。针对EGFR的酪氨酸激酶抑制剂(TKI)，如Erlotinib，能够阻止非小细胞肺癌的这些促癌特性。第三代EGFR TKI，如Osimertinib，正专注于导致获得性TKI耐药。在这里，我们报告了一例转移性非小细胞肺癌患者的临床过程，该患者接受了EGFR靶向治疗，并受到TKI获得性耐药的进一步挑战。她延长的存活期和维持的生活质量是这些现代的、针对基因型的、个性化的转移性非小细胞肺癌治疗的结果。
Specific oncogenes with driver mutations, such as the Epidermal Growth Factor Receptor (EGFR 1) gene can lead to non-small-cell lung cancer formation. Identification of these oncogenes, their driver mutations and downstream effects allow the targeting of these pathways by drugs. Such personalised therapy has become an important strategy in combating lung cancer and highlights the need to test for these mutations. Tyrosine Kinase Inhibitors (TKIs) against EGFR, such as Erlotinib, are able to halt these tumour promoting properties in non-small-cell lung cancers. Third generation EGFR TKIs, such as Osimertinib, are focussing on resulting acquired TKI resistance. Here we report the clinical course of a patient with metastatic non-small-cell lung cancer who has undergone EGFR targeted therapy and been further challenged by TKI acquired resistance. Her extended survival and maintained quality of life are a consequence of these modern, genotype-targeted, personalised metastatic non-small-cell lung cancer therapies.